Depression, Inflammation, and the Moderating Role of Metformin: Results From the Midlife in the United States Study and Sacramento Area Latino Study on Aging.

IF 2.9 3区医学 Q2 PSYCHIATRY Psychosomatic Medicine Pub Date : 2024-06-01 Epub Date: 2023-10-24 DOI:10.1097/PSY.0000000000001257

Sumaiyah U Syed, Jared I Cortez, Stephanie J Wilson

{"title":"Depression, Inflammation, and the Moderating Role of Metformin: Results From the Midlife in the United States Study and Sacramento Area Latino Study on Aging.","authors":"Sumaiyah U Syed, Jared I Cortez, Stephanie J Wilson","doi":"10.1097/PSY.0000000000001257","DOIUrl":null,"url":null,"abstract":"Objective: Depression can promote inflammation and accelerate aging. Metformin, a widely prescribed antidiabetic, has shown promising preclinical evidence of aging-related health benefits, including decreased inflammation. The current study examined whether metformin usage buffers the association between depressive symptoms and inflammatory markers in two large samples of middle-aged and older, primarily White adults, and older Latino adults.Methods: Data from the Midlife in the United States Study ( N = 1255) and the Sacramento Area Latino Study on Aging ( N = 1786) included information on medication use, depressive symptoms, and inflammatory markers, namely, interleukin 6 (IL-6), tumor necrosis factor α, and C-reactive protein (CRP). These data were merged into a harmonized sample, and the sample group variable was included in a three-way interaction for analysis.Results: Specifically, in the Midlife in the United States Study sample, metformin buffered the association between depressive symptoms and CRP ( b = -0.029, standard error [SE] = 0.013, p = .007) and IL-6 ( b = 0.21, SE = 0.010, p = .046), whereas no significant association was found with tumor necrosis factor α. Metformin nonusers displayed higher depressive symptoms associated with elevated CRP ( b = 0.01, SE = 0.003, p < .001) and IL-6 ( b = 0.011, SE = 0.003, p < .001), whereas this association was not present among metformin users ( p values > .068). Conversely, in the Sacramento Area Latino Study on Aging sample, metformin use did not show a significant protective link.Conclusions: Results from mostly White, highly educated adults supported a mitigating role of metformin in ties between depression, a well-known behavioral risk factor, and inflammation, a key source of biological aging. However, the benefits did not extend to a large sample of older Mexican Americans. The findings reveal a hidden potential benefit of this therapeutic agent and raise important questions around its health equity.Trial registration: The study was preregistered on OSF ( https://osf.io/c92vw/ ).","PeriodicalId":20918,"journal":{"name":"Psychosomatic Medicine","volume":" ","pages":"473-483"},"PeriodicalIF":2.9000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11039570/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychosomatic Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/PSY.0000000000001257","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/24 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Depression can promote inflammation and accelerate aging. Metformin, a widely prescribed antidiabetic, has shown promising preclinical evidence of aging-related health benefits, including decreased inflammation. The current study examined whether metformin usage buffers the association between depressive symptoms and inflammatory markers in two large samples of middle-aged and older, primarily White adults, and older Latino adults.

Methods: Data from the Midlife in the United States Study ( N = 1255) and the Sacramento Area Latino Study on Aging ( N = 1786) included information on medication use, depressive symptoms, and inflammatory markers, namely, interleukin 6 (IL-6), tumor necrosis factor α, and C-reactive protein (CRP). These data were merged into a harmonized sample, and the sample group variable was included in a three-way interaction for analysis.

Results: Specifically, in the Midlife in the United States Study sample, metformin buffered the association between depressive symptoms and CRP ( b = -0.029, standard error [SE] = 0.013, p = .007) and IL-6 ( b = 0.21, SE = 0.010, p = .046), whereas no significant association was found with tumor necrosis factor α. Metformin nonusers displayed higher depressive symptoms associated with elevated CRP ( b = 0.01, SE = 0.003, p < .001) and IL-6 ( b = 0.011, SE = 0.003, p < .001), whereas this association was not present among metformin users ( p values > .068). Conversely, in the Sacramento Area Latino Study on Aging sample, metformin use did not show a significant protective link.

Conclusions: Results from mostly White, highly educated adults supported a mitigating role of metformin in ties between depression, a well-known behavioral risk factor, and inflammation, a key source of biological aging. However, the benefits did not extend to a large sample of older Mexican Americans. The findings reveal a hidden potential benefit of this therapeutic agent and raise important questions around its health equity.

Trial registration: The study was preregistered on OSF ( https://osf.io/c92vw/ ).

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

抑郁症、炎症和二甲双胍的调节作用：来自美国中年研究（MIDUS）和萨克拉门托地区拉丁裔老龄化研究（SALSA）的结果。

目的：抑郁症能促进炎症，加速衰老。二甲双胍是一种广泛使用的抗糖尿病药物，已显示出与衰老相关的健康益处的有希望的临床前证据，包括减少炎症。目前的研究考察了二甲双胍的使用是否能缓冲两个大样本中老年人（主要是白人成年人和拉丁裔老年人）的抑郁症状和炎症标志物之间的关联。方法：来自美国中年研究（MIDUS；N=1255）和萨克拉门托地区拉丁裔老龄化研究（SALSA；N=1786）的数据包括药物使用、抑郁症状和炎症标志物，即IL-6、TNF-α和CRP的信息。将这些数据合并到一个统一的样本中，并将样本组变量纳入三方交互作用中进行分析。结果：具体而言，在MIDUS样本中，二甲双胍缓冲了抑郁症状与CRP（b=0.029，SE=0.013，p=0.007）和IL-6（b=0.21，SE=0.010，p=0.046）之间的相关性，而与TNF-α没有发现显著相关性。非二甲双胍使用者表现出较高的抑郁症状，与CRP（b=0.01，SE=0.003，p<.001）和IL-6（b=0.011，SE=0.0003，p<0.001）升高相关，而二甲双胍使用者中不存在这种相关性（p>.068）。相反，在SALSA样本中，二甲双胍的使用没有显示出显著的保护作用。结论：大多数受过高等教育的白人成年人的研究结果支持二甲双胍在抑郁症（一种众所周知的行为风险因素）和炎症（生物衰老的关键来源）之间的关系中的缓解作用。然而，这些福利并没有扩大到大量墨西哥裔老年美国人。研究结果揭示了这种治疗剂隐藏的潜在益处，并围绕其健康公平性提出了重要问题。试验注册：该研究已在OSF上预先注册(https://osf.io/c92vw/)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Psychosomatic Medicine 医学-精神病学

CiteScore

5.10

自引率

0.00%

发文量

258

审稿时长

4-8 weeks

期刊介绍： Psychosomatic Medicine is the official peer-reviewed journal of the American Psychosomatic Society. The journal publishes experimental, clinical, and epidemiological studies on the role of psychological and social factors in the biological and behavioral processes relevant to health and disease. Psychosomatic Medicine is an interdisciplinary peer-reviewed journal devoted to high-quality science on biobehavioral mechanisms, brain-behavior interactions relevant to physical and mental disorders, as well as interventions in clinical and public health settings. Psychosomatic Medicine was founded in 1939 and publishes interdisciplinary research articles relevant to medicine, psychiatry, psychology, and other health-related disciplines. The print journal is published nine times a year; most articles are published online ahead of print. Supplementary issues may contain reports of conferences at which original research was presented in areas relevant to the psychosomatic and behavioral medicine.